Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO21 Expert Video Report on colorectal cancer

Reporting from the ESMO Congress 2021, Filippo Pietrantonio discusses the results from the FOCUS4-C trial on adavosertib in TP53 and RAS mutant metastatic colorectal cancer patients. He also covers results from the MAYA trial investigating strategies based on molecular selection and hypermutation induction to turn microsatellite stable metastatic colorectal cancer sensitive to immunotherapy.

382O: Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing Adavosertib (AZD1775) with active monitoring - Dr Jenny Seligmann, GB

383O: MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC) - Dr Filippo Pietrantonio, IT

The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.